# OnCo record juliet (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/juliet/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "juliet", "NCT02445248" ;
  schema:name "JULIET"@en ;
  schema:alternateName "CTL019 in diffuse large B-cell lymphoma"@en, "JULIET trial"@en ;
  schema:description "The pivotal study of the second CAR-T cell product approved for adult lymphoma, which put about a third of people with no remaining options into a lasting remission."@en ;
  schema:url <https://onco.cc/trials/juliet/> ;
  schema:dateModified "2026-10-01"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02445248>, <https://doi.org/10.1056/NEJMoa1804980> ;
  onco:status "positive" ;
  onco:tag "lymphoma-evidence" ;
  onco:phase "2" ;
  schema:startDate "2015-07-29" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/cd19/> ;
  onco:drugs <https://onco.cc/drugs/tisagenlecleucel/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:terms <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/>, <https://onco.cc/terms/bridging-therapy/>, <https://onco.cc/terms/lymphodepletion/>, <https://onco.cc/terms/lymphoma-tx-car-t-pathway/> ;
  onco:trials <https://onco.cc/trials/zuma-1/>, <https://onco.cc/trials/belinda/>, <https://onco.cc/trials/transform/>, <https://onco.cc/trials/zuma-7/> ;
  onco:people <https://onco.cc/people/stephen-schuster/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/>, <https://onco.cc/bottlenecks/b-global-access/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-juliet-tisagenlecleucel-dlbcl-nejm-2019/> .